Evidence map›Paper›PMID 27713173›Full record

ArticleOncotarget2016

Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.

Yang Qu, Li Liu, Jiajun Wang, Wei Xi, Yu Xia, Qi Bai, Ying Xiong, Qilai Long, Jiejie Xu, Jianming Guo

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. A novel role of DOT1L in kidney diseases.Molecular biology reports · 2023
    Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yang QuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Li LiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiajun WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Wei XiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yu XiaDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Qi BaiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Ying XiongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Qilai LongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiejie XuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Sun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNFudan University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisruptor of telomeric silencing 1-like (Dot1l), a histone methyltransferase that targets the histone H3 lysine 79 (H3K79), has been reported that its high expression is associated with various cancers, while the association between Dot1l expression and clear-cell renal cell carcinoma (ccRCC) is still unknown. PATIENTS AND

methodsWe retrospectively enrolled 282 patients with ccRCC undergoing nephrectomy from a single institution between 2005 and 2007, with a median follow-up of 99 months. Dot1l expression was evaluated by immunohistochemistry in clinical specimens. We compared the clinical outcomes by Kaplan-Meier survival analyses and assessed the prognostic value of Dot1l expression. Harrell's concordance index (C-index) was used to assess the predictive accuracy of different prognostic models.

resultsHigher Dot1l expression indicated poorer OS (P<0.001) and RFS (P<0.001) in patients with ccRCC. Moreover, Dot1l expression could stratify ccRCC patients in pT stage, Fuhrman grade and SSIGN/ Leibovich subgroups, which might redefine individual risk stratification. Multivariate analyses further indicated that Dot1l expression was an independent prognostic factor for OS (P=0.007) and RFS (P=0.001). The prognostic accuracy of conventional prognostic models was notably improved with Dot1l integration. Two nomograms and calibration plots were built to predict OS and RFS for patients with ccRCC and performed better based on C-index value.

conclusionDot1l expression is a promising independent prognostic indicator for postoperative recurrence and survival of patients with ccRCC.

Indexed as

NephrectomyAdultAgedCarcinoma, Renal CellFemaleFollow-Up StudiesHistone-Lysine N-MethyltransferaseHumansKidney NeoplasmsMaleMethyltransferasesMiddle AgedNeoplasm StagingPostoperative ComplicationsPredictive Value of TestsPrognosisDOT1L protein, humanHistone-Lysine N-MethyltransferaseMethyltransferasesclear-cell renal cell carcinomaDot1lnomogramoverall survivalprognostic biomarker

Identifiers

PMID27713173
PMCPMC5356697
OpenAlexW2541768492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.